<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11027739
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     10
    </month>
    <day>
     12
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     10
    </month>
    <day>
     12
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0028-4793
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       343
      </volume>
      <issue>
       15
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Oct
       </month>
       <day>
        12
       </day>
      </pubdate>
     </journalissue>
     <title>
      The New England journal of medicine
     </title>
     <isoabbreviation>
      N. Engl. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group.
    </articletitle>
    <pagination>
     <medlinepgn>
      1054-63
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Antiinflammatory therapies, such as inhaled corticosteroids or nedocromil, are recommended for children with asthma, although there is limited information on their long-term use.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We randomly assigned 1041 children from 5 through 12 years of age with mild-to-moderate asthma to receive 200 microg of budesonide (311 children), 8 mg of nedocromil (312 children), or placebo (418 children) twice daily. We treated the participants for four to six years. All children used albuterol for asthma symptoms.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      There was no significant difference between either treatment and placebo in the primary outcome, the degree of change in the forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. As compared with the children assigned to placebo, the children assigned to receive budesonide had a significantly smaller decline in the ratio of FEV1 to forced vital capacity (FVC, expressed as a percentage) before the administration of a bronchodilator (decline in FEV1:FVC, 0.2 percent vs. 1.8 percent). The children given budesonide also had lower airway responsiveness to methacholine, fewer hospitalizations (2.5 vs. 4.4 per 100 person-years), fewer urgent visits to a caregiver (12 vs. 22 per 100 person-years), greater reduction in the need for albuterol for symptoms, fewer courses of prednisone, and a smaller percentage of days on which additional asthma medications were needed. As compared with placebo, nedocromil significantly reduced urgent care visits (16 vs. 22 per 100 person-years) and courses of prednisone. The mean increase in height in the budesonide group was 1.1 cm less than in the placebo group (22.7 vs. 23.8 cm, P=0.005); this difference was evident mostly within the first year. The height increase was similar in the nedocromil and placebo groups.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      In children with mild-to-moderate asthma, neither budesonide nor nedocromil is better than placebo in terms of lung function, but inhaled budesonide improves airway responsiveness and provides better control of asthma than placebo or nedocromil. The side effects of budesonide are limited to a small, transient reduction in growth velocity.
     </abstracttext>
    </abstract>
    <language>
     eng
    </language>
    <grantlist completeyn="N">
     <grant>
      <grantid>
       N01-HR-16044
      </grantid>
      <acronym>
       HR
      </acronym>
      <agency>
       NHLBI NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
     <grant>
      <grantid>
       N01-HR-16045
      </grantid>
      <acronym>
       HR
      </acronym>
      <agency>
       NHLBI NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
     <grant>
      <grantid>
       N01-HR-16046
      </grantid>
      <acronym>
       HR
      </acronym>
      <agency>
       NHLBI NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     N Engl J Med
    </medlineta>
    <nlmuniqueid>
     0255562
    </nlmuniqueid>
    <issnlinking>
     0028-4793
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Asthmatic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Glucocorticoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      51333-22-3
     </registrynumber>
     <nameofsubstance>
      Budesonide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      53-03-2
     </registrynumber>
     <nameofsubstance>
      Prednisone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      69049-73-6
     </registrynumber>
     <nameofsubstance>
      Nedocromil
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2004 Dec 16;351(25):2654-5; author reply 2654-5
     </refsource>
     <pmid version="1">
      15602028
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2001 Feb 22;344(8):607; author reply 607-8
     </refsource>
     <pmid version="1">
      11221624
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2001 Feb 22;344(8):607; author reply 607-8
     </refsource>
     <pmid version="1">
      11221625
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2000 Oct 12;343(15):1113-4
     </refsource>
     <pmid version="1">
      11027747
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Inhalation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Asthmatic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Asthma
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Budesonide
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Forced Expiratory Volume
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glucocorticoids
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Growth
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hospitalization
     </descriptorname>
     <qualifiername majortopicyn="N">
      statistics &amp; numerical data
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lung
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      growth &amp; development
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Nedocromil
     </descriptorname>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prednisone
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vital Capacity
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      10
     </month>
     <day>
      12
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      10
     </month>
     <day>
      18
     </day>
     <hour>
      11
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      10
     </month>
     <day>
      12
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11027739
    </articleid>
    <articleid idtype="doi">
     10.1056/NEJM200010123431501
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

